Anjana Pillai to Middle Aged
This is a "connection" page, showing publications Anjana Pillai has written about Middle Aged.
Connection Strength
0.440
-
Prevention, Diagnosis, and Treatment of Hepatocellular Carcinoma. JAMA. 2024 09 24; 332(12):1013-1014.
Score: 0.063
-
Lymphoepithelioma-Like Carcinomas: A Rare Variant of Cholangiocarcinoma. Hepatology. 2020 07; 72(1):353-355.
Score: 0.047
-
A Patient With an Elevated a-Fetoprotein Level and Liver Masses. JAMA. 2019 Jan 01; 321(1):97-98.
Score: 0.042
-
Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin. Aliment Pharmacol Ther. 2017 06; 45(11):1427-1432.
Score: 0.037
-
Caution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy. Am J Gastroenterol. 2016 Dec; 111(12):1854-1856.
Score: 0.037
-
Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience. Am J Gastroenterol. 2016 Feb; 111(2):250-60.
Score: 0.034
-
Indwelling peritoneal catheters in patients with cirrhosis and refractory ascites. Intern Med J. 2015 Oct; 45(10):1026-31.
Score: 0.034
-
Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C. Transplant Proc. 2010 Nov; 42(9):3647-51.
Score: 0.024
-
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction. JAMA Oncol. 2024 Sep 01; 10(9):1253-1258.
Score: 0.016
-
Modified Radiation Lobectomy Strategy of Radioembolization for Right-Sided Unresectable Primary Liver Tumors. J Vasc Interv Radiol. 2024 Jul; 35(7):989-997.e2.
Score: 0.015
-
Tumor Size and Watershed Area Correlate with Incomplete Treatment and Tumor Progression after Selective Radioembolization for Hepatocellular Carcinoma. J Vasc Interv Radiol. 2024 May; 35(5):712-721.e3.
Score: 0.015
-
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. Eur J Cancer. 2021 11; 157:140-152.
Score: 0.013
-
Safety and efficacy of repeat Y90 radioembolization to the same hepatic arterial territory. Br J Radiol. 2021 Mar 01; 94(1119):20200752.
Score: 0.012
-
Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology. 2019 11; 157(5):1253-1263.e2.
Score: 0.011
-
Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Gastroenterology. 2019 05; 156(6):1683-1692.e1.
Score: 0.011
-
Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study. Am J Gastroenterol. 2016 09; 111(9):1297-304.
Score: 0.009
-
Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study. J Gastroenterol Hepatol. 2015 Jul; 30(7):1167-74.
Score: 0.008
-
Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir. Clin Infect Dis. 2015 Oct 15; 61(8):1304-6.
Score: 0.008
-
Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2008 May; 6(5):584-9.
Score: 0.005